
AUSTRALIA has committed K4.2 million to support Papua New Guinea’s historic introduction of the human papillomavirus (HPV) vaccine, in a major effort to protect girls from cervical cancer.
The funding will support PNG’s initial nationwide rollout of HPV vaccinations, targeting almost 900,000 girls aged between nine and 14 years.
Announcing the support on World Cervical Cancer Elimination Day, Australia said the contribution would strengthen PNG’s efforts to prevent cervical cancer and improve the health and wellbeing of women and girls.
Cervical cancer is the second most common cancer among women in Papua New Guinea, with approximately 1,053 new cases recorded annually.
The HPV vaccine is expected to play a significant role in reducing the disease burden and protecting future generations from cervical cancer.
Australia’s funding will assist healthcare workers in delivering the nationwide vaccination campaign, alongside community awareness and engagement activities, training and supervision.
The initiative will also focus on reaching girls who are out of school and those living in remote and hard-to-reach communities to ensure wider vaccination coverage.
Australia’s High Commissioner to Papua New Guinea, H.E. Jamie Isbister, said Australia was proud to support PNG’s first rollout of the HPV vaccine.
“ This game-changing vaccine, developed by Australian researchers, will provide a lifetime of protection against cervical cancer for young girls across the country,” Mr Isbister said.
The vaccination programme will be implemented in partnership with the Government of Papua New Guinea and technical partners, including UNICEF, the World Health Organization (WHO) and Gavi, the Vaccine Alliance.
Australia said it remained committed to supporting PNG to strengthen immunisation coverage and advance efforts towards a future free from cervical cancer.
